Developer of an anti-CD40 monoclonal antibody therapy intended to offer treatment of chronic inflammatory diseases like primary biliary cirrhosis and Crohn's disease. The company's anti-CD40 monoclonal antibody therapy is a negative allosteric modulator of the CD40 pathway and functions as a reversible switch for B cell activation and inhibits immune responses, enabling doctors to offer treatment for chronic inflammatory and autoimmune diseases.
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
2. Out of Business | 01-Sep-2016 | 00.000 | Completed | Out of Business | ||
1. Early Stage VC (Series A) | 23-Jan-2013 | 00.000 | 00.000 | Completed | Startup |
Name | Representing | Role | Since |
---|---|---|---|
Bram Vanparys Ph.D | PMV | Supervisory Board Member | 000 0000 |
Kevin Johnson Ph.D | Index Ventures | Board Member | 000 0000 |
Stéphane Verdood | Vesalius Biocapital Partners | Supervisory Board Member | 000 0000 |